Skip to main content

Innovatus Life Sciences Acquisition Corp. (ILAC)

Innovatus Life Sciences Acquisition will go public soon, but the exact IPO date is still unknown.
Stock Price: $10.00
Confirmed IPO price

Company Description

Innovatus Life Sciences Acquisition Corp. is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

We intend to initially focus our search on identifying a prospective target business in the life sciences sector. Our sponsor is an affiliate of Innovatus Capital Partners, LLC, a boutique private equity firm with 27 professionals focused on creating value in special situations, growth equity, emerging asset classes, private credit and asset-based investments.

Since 2017, Innovatus Capital has evaluated numerous life sciences companies, investing in 15 companies and deployed over $370 million in capital to, among others, Personal Genome Diagnostics, Biodesix, Inc., Biotheranostics and Bionano Genomics, Inc.

Innovatus Life Sciences Acquisition Corp.
CountryUnited States
IPO DatePending
IndustryBlank Checks / SPAC
CEODavid Schiff

Contact Details

777 Third Avenue, 25th Floor
New York, NY 10017
United States
Phone(212) 698-4580

Stock Details

Ticker SymbolILAC
Reporting CurrencyUS Dollars
IPO Price$10.00
CIK Code1846550
Employer ID86-155316

Key Executives

David SchiffChief Executive Officer and Chairman of the Board of Directors
Andrew HobsonChief Financial Officer and Director
Claes EkstromChief Business Officer